Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
13 déc. 2022 08h00 HE
|
Immix Biopharma, Inc.
In December 2022, the 15th patient was dosed with IMX-110IMX-110 clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans...
ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing
12 déc. 2022 08h00 HE
|
Immix Biopharma, Inc.
LOS ANGELES, CA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics...
Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher
11 nov. 2022 08h00 HE
|
Immix Biopharma, Inc.
Enrolling pediatric patients in a clinical trial is a key requirement for FDA approval of a Priority Review Voucher (“PRV”)While their future value is uncertain, PRVs are transferable to other...
Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26
25 oct. 2022 08h00 HE
|
Immix Biopharma, Inc.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe1f9d2e-f230-494b-9bb9-6b910a14f2aa LOS ANGELES, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Immix...
ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site
18 oct. 2022 08h00 HE
|
Immix Biopharma, Inc.
California Soft Tissue Sarcoma Site to lead expanded clinical site consortiumHistorically, high-enrolling lead site has enrolled 2-3 patients per monthClinical trial data expected to be released on a...
ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials
07 sept. 2022 12h05 HE
|
Immix Biopharma, Inc.
Scaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials:2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”)2022 planned combination IMX-110 +...
ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study
20 mai 2022 08h47 HE
|
Immix Biopharma, Inc.
One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug)In a connective tissue cancer Soft...
Immix Biopharma Announces Share Repurchase Program
09 mai 2022 08h00 HE
|
Immix Biopharma, Inc.
LOS ANGELES, May 09, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM...
ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day Event Held on April 5, 2022
05 avr. 2022 09h30 HE
|
Immix Biopharma, Inc.
The IMMX Milestone Day Event is viewable at www.immixbio.com/Apr2022MilestoneDayManagement discussed financial position, milestones, and new opportunities presented by current market...
Immix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022
07 mars 2022 08h00 HE
|
Immix Biopharma, Inc.
Management plans to discuss current financial position, milestones, and new opportunities presented by current market volatilityWith $24.2 million gross proceeds from its December 2021 IPO, ImmixBio...